The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl)

Lindsay PC, Peter Lindsay, P C Lindsay, Shaw RW, Robert W. Shaw, R W Shaw, Herjan J.T. Coelingh Bennink, Bennink HJ, H J Bennink, P Kicovic, P. M. Kicovic, Kicovic P
Fertility and sterility · 1996 · vol. 65(2) , pp. 342–348 · doi:10.1016/s0015-0282(16)58096-0 · PMID:8566259 · W1591340500
Non-randomised trial OA: closed CC0 ⤵ 44 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study investigated the efficacy of tibolone add-back therapy in women undergoing treatment with the GnRH agonist triptorelin for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To assess whether tibolone can prevent the bone loss and symptomatic side effects normally associated with GnRH agonist (GnRH-a) use and whether tibolone modifies the effect of GnRH-a on endometriosis. DESIGN: Prospective, double-blind, placebo-controlled, group comparative study. SETTING: Gynecological research unit in a London teaching hospital. PATIENTS: Twenty-nine patients with endometriosis and two with fibroids. INTERVENTIONS: Six months of treatment with 3.75 mg/mo IM triptorelin combined with daily tablets of either placebo or 2.5 mg tibolone. MAIN OUTCOME MEASURES: Daily symptom diary for hot flushes and bleeding episodes, laparoscopic scoring of endometriosis, endocrine and biochemical changes, and bone mineral density scans. RESULTS: Lumbar spine bone mineral density decreased significantly from baseline in the placebo group (-5.1%) but not in the tibolone group (-1.1%). The frequency of hot flushes and sweating episodes was reduced significantly by tibolone. There was no difference between the two treatment groups with regard to the endometriosis scores. CONCLUSIONS: The addition of tibolone to GnRH-a treatment reduces the bone loss and vasomotor symptoms that normally occur with GnRH-a, thus making long-term treatment with GnRH-a safer and more acceptable. It does not negate the therapeutic effect of GnRH-a on endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Anabolic Agents Bone Density Endometriosis Leiomyoma Luteolytic Agents Norpregnenes Triptorelin Pamoate Uterine Neoplasms Adult Adult Anabolic Agents Anabolic Agents Bone Density Bone Density Double-Blind Method Double-Blind Method Drug Interactions Drug Interactions Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (27)

Cited by (44)

Source provenance

europepmc
last seen: 2026-10-09T06:09:53.026058+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:59:43.143194+00:00
License: CC0 · commercial use OK